The Future of Peptide Access
July 23-24, 2026: Pharmacy Compounding Advisory Committee
The FDA committee will review peptides nominated for the 503A compounding list. The outcome shapes whether physicians and pharmacists keep access to safe, regulated compounded peptides for their patients. This is your hub to follow the hearing and take action.
The decision affects patient access, cost, and whether care stays in regulated channels rather than an unregulated gray market.
Public comments close July 22, 2026. Comments filed by July 9 are provided directly to the committee, so submitting early carries more weight.
Peptide Therapy Access Hangs on an FDA Advisory Vote
The FDA is about to weigh in on the future of access to certain peptide therapies. On July 23 and 24, 2026, an advisory committee considers whether licensed pharmacies can prepare these therapies for patients who have a prescription. If that regulated access narrows, patients do not stop seeking care. They get pushed toward an unregulated gray market that is genuinely dangerous. Here is what is at stake, in plain English, and how to add your voice before the comment window closes.
Safe, regulated access
A licensed pharmacy prepares a therapy under a valid prescription, with verified quality and a clinician’s oversight. That is the regulated, supervised access this hearing puts at risk.
An unregulated gray market
When regulated access narrows, patients do not stop. They turn to online vendors and products labeled “for research use only,” with no quality control, no verified dosing, and no medical supervision.
The hearing decides which path patients are left with. AAPM’s position is to ensure access is safe and regulated.
What is a peptide?
A short chain of amino acids, the same building blocks that make up proteins. Your body makes thousands of them, insulin has been one for over a century, and they are in everyday foods.
Read moreWhat is the PCAC hearing?
The Pharmacy Compounding Advisory Committee advises the FDA. On July 23 and 24, 2026, it meets to consider whether licensed pharmacies can prepare certain peptide therapies for patients who have a prescription. Its vote is a recommendation, not a final rule.
Read moreWhat is at stake?
Patients could lose safe, regulated access to therapies they rely on. If that access narrows, care does not stop. It shifts toward an unregulated gray market with no quality control, no verified dosing, and no medical supervision.
Read moreWhy this matters
Patients
For people managing chronic conditions, this is about whether a therapy that is helping them stays available through a regulated pharmacy instead of an unregulated gray market.
Compounding pharmacists
Accredited 503A and 503B pharmacies are inspected and held to standards. The hearing affects their ability to prepare these therapies for the patients who are prescribed them.
Clinicians
Prescribers want a safe, regulated supply they can trust, so care stays in accountable channels rather than pushing patients to self-source.
The real question is simple: does the current rule make patients safer, or does it hand them to a market with no rules at all?
Two Ways to Make Your Voice Heard
Follow the hearing and tell the FDA where you stand. Both take less than a minute.
Follow the Hearing
Sign up to get the livestream link and action alerts as the hearing approaches.
Tell the FDA Your Position
The FDA is accepting public comments on the peptides under review. A comment in your own words carries more weight than a form letter, so personalize the starting text below, then submit it on the official FDA portal. Comments filed by July 9, 2026 are provided directly to the committee.
- How access to regulated compounded peptides affects you or your patients
- Why oversight by accredited pharmacies and licensed providers matters
- The risk of pushing patients toward an unregulated market
- Your own clinical, professional, or personal experience
Editing the text in your own words makes your comment more effective. Your edits stay only in your browser and reset if you refresh the page.
Submit Your Comment on regulations.govAfter you submit, save the Comment Tracking Number you receive for your records.
Comment window closes July 22, 2026.
More ways to take action, including a tool to write your representative, are coming soon.
Watch the Hearing Live
The FDA streams the PCAC meeting on July 23-24, 2026. The live video appears here once it begins.
Livestream goes live July 23, 2026
Sign up above and we will email you the link the moment the stream starts.
Key dates
- July 9, 2026Early comment deadlineComments filed by this date are provided directly to the committee.
- July 22, 2026Comment period closesThe last day to submit your comment on regulations.gov.
- July 23 to 24, 2026The PCAC hearingThe committee meets and votes on its recommendation to the FDA.
A committee vote is a recommendation to the FDA, not a final rule.